SCHEMBL6534830

SCHEMBL6534830

COC(OP(=O)(O)O)c1cnc(C)c(O)c1CO

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ HPGD P15428 2/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ LMNA P02545 3/20 0.39
▸ ESR1 P03372 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ ACP1 P24666 1/20 0.39
▸ PDE4A P27815 1/20 0.39
▸ P2RX1 P51575 1/20 0.39
▸ P2RX2 Q9UBL9 1/20 0.39
▸ PNPO Q9NVS9 1/20 0.38
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ AOX1 Q06278 1/20 0.35
▸ TRIM24 O15164 1/20 0.35
▸ TRIM33 Q9UPN9 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4576782 0.81 KDM4E (0.47) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL4576376 0.77 KDM4E (0.50) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL4577607 0.76 HPGD (0.51) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL4577063 0.76 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL13988518 0.74 KDM4E (0.50) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL4577021 0.72 KDM4E (0.44) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL29384180 0.70 ESR1 (0.64) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL43880 0.70 ESR1 (0.64) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL5420563 0.70 KDM4E (0.45) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL4576775 0.70 KDM4E (0.45) KDM4EALDH1A1HPGDHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040121988-A1 Treatment of cerebrovascular disease MEDICURE INTERNATIONAL INC. (BB) 2004-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121988-A1 Treatment of cerebrovascular disease PNPO, PLPBP, PDXK KDM4E 1621/4885ALDH1A1 1627/4885HPGD 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback